Next-generation anti-inflammatory small-molecule leads

Chronic inflammatory disorders are commonly managed with NSAIDs or corticosteroids, but long-term use is often associated with gastrointestinal, renal, cardiovascular, and immunological risks. This limits sustained treatment and can reduce patient adherence. There is a clear need for new anti-inflammatory agents with effective activity and an improved tolerability profile.

The invention introduces the novel compounds zymonic acid and ZOMPD as anti-inflammatory leads for the treatment of inflammatory diseases. They are designed to act directly on inflammatory mechanisms rather than relying on broadly acting standard approaches. Early data indicate suppression of key cytokines which promote inflammatory reactions. The compounds may offer a basis for safer stand-alone or combination therapies and can be developed in multiple dosage forms, including oral formulations.